Q3 2024 EPS Estimates for AngioDynamics, Inc. Reduced by Zacks Research (NASDAQ:ANGO)

AngioDynamics, Inc. (NASDAQ:ANGO – Free Report) – Zacks Research lowered their Q3 2024 earnings per share (EPS) estimates for AngioDynamics in a research report issued on Wednesday, March 13th. Zacks Research analyst D. Dey now expects that the medical instruments supplier will earn ($0.15) per share for the quarter, down from their previous forecast of […]

Leave a Reply

Your email address will not be published.

Previous post Short Interest in Apogee Therapeutics, Inc. (NASDAQ:APGE) Declines By 5.2%
Next post Zacks Research Analysts Lower Earnings Estimates for Repligen Co. (NASDAQ:RGEN)